About
Immuno-Oncology
Areas of Focus
Categories
Biologics & BiopharmaceuticalAntibodyBiotech
Clinical Trials (6)
View allTotal Trials
6
As Lead Sponsor
5
As Collaborator
1
Total Enrollment
768
By Phase
PHASE1: 4NA: 1PHASE1/PHASE2: 1
By Status
COMPLETED: 5RECRUITING: 1
Clinical Trials Pipeline6 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2019
2020
2021
2022
2023
2024
2025
2026
2027
Today
Hover over trial bars to see details
Recent Trials
NCT05508100Lead Sponsor
Dose Confirmation and Dose Expansion Phase 1 Study of IO-108 and IO-108 + Anti-PD-1 in Solid Tumors
PHASE1Completed
38 participants
Started: Sep 9, 2022 · Completed: Apr 30, 2024
NCT05309187Lead Sponsor
Dose-Escalation and Dose-Expansion Study of IO-202 and IO-202+Pembrolizumab in Solid Tumors
PHASE1Completed
22 participants
Started: Apr 11, 2022 · Completed: May 31, 2024
NCT05054348Lead Sponsor
First-in-human Study of IO-108 as Single Agent and in Combination With a PD-1 Immune Check Point Inhibitor in Patients With Advanced Solid Tumors
PHASE1Completed
91 participants
Started: Sep 30, 2021 · Completed: May 31, 2024
NCT05242718Lead Sponsor
Immune Diversity Response to Oral Dosing of Nutritional Health Products in Healthy Participants
NACompleted
32 participants
Started: Jan 10, 2021 · Completed: May 20, 2021
NCT04524871Collaborator
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)
PHASE1/PHASE2Recruiting
518 participants
Started: Nov 1, 2020 · Completed: Dec 31, 2026
Funding History (1)
D
Sep 21, 2016
Locations (1)
Headquarters
Palo Alto, CA, United States
Map
Loading map...